Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
OncoTargets and Therapy is Scopus-indexed (Q2, CiteScore 4.7), WoS SCIE. Published by Dove Medical Press Ltd.
Checked against the index lists dated .
ISSN 1178-6930Verify ISSN ↗
Publisher: Dove Medical Press Ltd
Cost to publish: About US$2,836 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 108 / 278 | 61st | Q2 |
| Oncology | 172 / 428 | 59th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2009–present, best quartile Q2, CiteScore 4.7.
OncoTargets and Therapy is Q2 in Pharmacology (medical) (rank 108 of 278) and Q2 in Oncology (rank 172 of 428), by CiteScore 2025.
OncoTargets and Therapy is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.7, which places it in quartile Q2 at the 61st percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.800, quartile Q2, with an H-index of 100.
The publisher lists an article processing charge of about US$2,836 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
OncoTargets and Therapy is published by Dove Medical Press Ltd. Its ISSN is 1178-6930.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal per Scopus.
OncoTargets and Therapy has an h-index of 114 and a 2-year mean of 2.16 citations per paper (OpenAlex). Its Scopus CiteScore is 4.7, quartile Q2. On 2-year citations it ranks #122 of 271 Scopus journals in Pharmacology (medical).
OncoTargets and Therapy published 104 papers in 2025; its busiest recent year was 2020 with 1,174. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 65 research articles (2025–2026), authors are most often from China (70%), Türkiye (3.1%) and Taiwan (3.1%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 520 retracted papers are recorded (76.7 per 1,000 papers). The Problematic Paper Screener flags 21 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.